Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of Roflumilast on Airway Blood Flow as an Expression of Airway Inflammation in COPD

Trial Profile

Effect of Roflumilast on Airway Blood Flow as an Expression of Airway Inflammation in COPD

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 27 Nov 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Roflumilast (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Oct 2015 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
    • 02 Dec 2014 Two treatment arms have been added.(Placebo single dose and Roflumilast 500µg single dose) as reported by ClinicalTrials.gov record.
    • 02 Dec 2014 Planned number of patients changed from 40 to 30 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top